LSD1-IN-24 (compound 3S) (0-50 mg/kg, oral gavage; daily for 2 weeks) inhibits in vivo MFC cell growth, tumor weight in a dose-dependent manner in a subcutaneous tumor model containing MFC cells Significantly decreased, tumor tissue Ki67 decreased significantly, and no obvious toxic effect on mice[1].
| Animal Model: | Male 615 mice with MFC cell[1] |
| Dosage: | 0, 10, 25, and 50 mg/kg |
| Administration: | Oral gavage; daily for 2 weeks |
| Result: | Significantly decreased intratumoral PD-L1 expression, increased CD3+, CD4+, CD8+ cell numbers, interleukin-2 (IL2) and IFNγ mRNA and protein levels were also upregulated. |